Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER 8: Oral Semaglutide Add-on to Insulin in T2D
NCT03021187Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2017
- Primary completion
- Jan 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03021187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021187.